SAB BIOTHERAPEUTICS, INC. Research and Development Expense
SAB BIOTHERAPEUTICS, INC. (SABS) reported Research and Development Expense of $16.17 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $16.17M, a 131.13% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $13.40M, a 74.97% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $10.73M, a 40.21% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $8.97M, a 14.55% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. research and development expense for fiscal 2025 was $34.35M, a 13.56% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. research and development expense for fiscal 2024 was $30.25M, a 83.18% increase from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. research and development expense for fiscal 2023 was $16.52M, a 54.68% decline from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. research and development expense for fiscal 2022 was $36.44M, a 36.28% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $16.17M 10-Q · filed 2026-08-06 | $29.57M 10-Q · filed 2026-08-06 | $40.30M derived: sum of 3 quarters · filed 2026-08-06 | $49.27M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $13.40M 10-Q · filed 2026-05-12 | $24.13M derived: sum of 2 quarters · filed 2026-05-12 | $33.10M derived: sum of 3 quarters · filed 2026-05-12 | $40.09M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $10.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $19.70M derived: sum of 2 quarters · filed 2026-03-09 | $26.70M derived: sum of 3 quarters · filed 2026-08-06 | $34.35M 10-K · filed 2026-03-09 | ||
| 2025-09-30 | $8.97M 10-Q · filed 2025-11-14 | $15.97M derived: sum of 2 quarters · filed 2026-08-06 | $23.62M 10-Q · filed 2025-11-14 | $31.28M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $7.00M 10-Q · filed 2026-08-06 | $7.00M 10-Q · filed 2025-08-07 | $14.65M 10-Q · filed 2026-08-06 | $14.65M 10-Q · filed 2025-08-07 | $22.31M derived: sum of 3 quarters · filed 2026-08-06 | $30.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $7.66M 10-Q · filed 2026-05-12 | $15.31M derived: sum of 2 quarters · filed 2026-05-12 | $23.14M derived: sum of 3 quarters · filed 2026-05-12 | $29.96M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $7.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $15.48M derived: sum of 2 quarters · filed 2026-03-09 | $22.30M derived: sum of 3 quarters · filed 2026-03-09 | $30.25M 10-K · filed 2026-03-09 | ||
| 2024-09-30 | $7.83M 10-Q · filed 2025-11-14 | $14.65M derived: sum of 2 quarters · filed 2025-11-14 | $22.60M 10-Q · filed 2025-11-14 | $27.10M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $6.82M 10-Q · filed 2025-08-07 | $14.77M 10-Q · filed 2025-08-07 | $19.27M derived: sum of 3 quarters · filed 2025-08-07 | $23.29M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $8.15M 10-Q · filed 2025-05-09 | $12.44M derived: sum of 2 quarters · filed 2025-05-09 | $16.46M derived: sum of 3 quarters · filed 2025-05-09 | $20.13M derived: sum of 4 quarters · filed 2025-05-09 | ||
| 2023-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $8.32M derived: sum of 2 quarters · filed 2025-03-31 | $11.98M derived: sum of 3 quarters · filed 2025-03-31 | $16.52M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $4.02M 10-Q · filed 2024-11-06 | $7.68M derived: sum of 2 quarters · filed 2024-11-06 | $12.22M 10-Q · filed 2024-11-06 | $19.36M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $3.66M 10-Q · filed 2024-08-08 | $8.20M 10-Q · filed 2024-08-08 | $15.34M derived: sum of 3 quarters · filed 2024-08-08 | $22.69M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $4.54M 10-Q · filed 2024-05-20 | $11.67M derived: sum of 2 quarters · filed 2024-05-20 | $19.03M derived: sum of 3 quarters · filed 2024-05-20 | $27.61M derived: sum of 4 quarters · filed 2024-05-20 | ||
| 2022-12-31 | $7.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $14.49M derived: sum of 2 quarters · filed 2024-03-29 | $23.08M derived: sum of 3 quarters · filed 2024-03-29 | $36.44M 10-K · filed 2024-03-29 | ||
| 2022-09-30 | $7.35M 10-Q · filed 2023-11-13 | $15.94M derived: sum of 2 quarters · filed 2023-11-13 | $29.30M 10-Q · filed 2023-11-13 | $39.91M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $8.58M 10-Q · filed 2023-08-21 | $21.95M 10-Q · filed 2023-08-21 | $32.56M derived: sum of 3 quarters · filed 2023-08-21 | $47.63M derived: sum of 4 quarters · filed 2023-08-21 | ||
| 2022-03-31 | $13.32M 10-Q · filed 2023-05-15 | $23.97M derived: sum of 2 quarters · filed 2023-05-15 | $39.04M derived: sum of 3 quarters · filed 2023-05-15 | $57.73M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $10.65M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28 | $25.72M derived: sum of 2 quarters · filed 2023-04-28 | $44.40M derived: sum of 3 quarters · filed 2023-04-28 | $57.18M 10-K/A · filed 2023-04-28 | ||
| 2021-09-30 | $15.07M 10-Q · filed 2022-11-14 | $33.75M derived: sum of 2 quarters · filed 2022-11-14 | $46.54M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $18.68M 10-Q · filed 2022-08-10 | $31.47M 10-Q · filed 2022-08-10 | ||||
| 2021-03-31 | $12.78M 10-Q · filed 2022-05-12 | |||||
| 2020-12-31 | $27.91M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |